Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, +239

The Lancet

Platinum–etoposide Versus Platinum–etoposideMedicinePharmacologyImmune Checkpoint InhibitorFirst-line Treatment +4

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, +247

The Lancet Oncology

Platinum–etoposide Versus Platinum–etoposideMedicinePathologyImmune Checkpoint InhibitorFirst-line Treatment +4

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

Eiki Ichihara, Katsuyuki Hotta, Naoyuki Nogami, +17

Journal of Thoracic Oncology

First-line TherapyPhase Ii TrialMedicinePathologyBronchial Neoplasm +6

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Luis Paz‐Ares, Óscar Juan, Giannis Mountzios, +193

Journal of Clinical Oncology

Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience

Katsuyuki Hotta, Katsuyuki Kiura, Nagio Takigawa, +17

Journal of Thoracic Oncology

MedicinePathologyBronchial NeoplasmGefitinib TreatmentCancer Treatment +4

A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705

Hiroshige Yoshioka, Katsuyuki Hotta, Katsuyuki Kiura, +10

Journal of Thoracic Oncology

Pretreated PatientsPhase Ii TrialMedicineErlotinib MonotherapyPathology +7

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

Hiroki Izumi, Shingo Matsumoto, Jie Liu, +35

Nature

Oncogenic AgentMedicineNon‐small‐cell Lung CancerPathologyCancer Cell Biology +8

Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

Shoichi Kuyama, Katsuyuki Hotta, Masahiro Tabata, +7

Journal of Thoracic Oncology

MedicineProtein StatusBronchial NeoplasmCancer TreatmentCancer Genetics +6

Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803

Akira Inoue, Shunichi Sugawara, Masao Harada, +9

Journal of Thoracic Oncology

OncologyMedicinePathologyPhase Ii StudyCancer Treatment +5

Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study

Yutaro Tamiya, Shingo Matsumoto, Yoshitaka Zenke, +18

Lung Cancer

Large-scale Clinico-genomic ProfileKras G12cTumor HeterogeneityMedicinePathology +9